Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.
Pamela Conley
Advertisement
Articles by Pamela Conley
Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
2
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
3
Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding
4
Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease
5
